Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and …
F Conforti, L Pala, I Sala, C Oriecuia, T De Pas… - Bmj, 2021 - bmj.com
Objective To evaluate pathological complete response as a surrogate endpoint for disease-
free survival and overall survival in regulatory neoadjuvant trials of early stage breast …
free survival and overall survival in regulatory neoadjuvant trials of early stage breast …
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino… - The Lancet, 2014 - thelancet.com
Background Pathological complete response has been proposed as a surrogate endpoint
for prediction of long-term clinical benefit, such as disease-free survival, event-free survival …
for prediction of long-term clinical benefit, such as disease-free survival, event-free survival …
Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline
LA Korde, MR Somerfield, LA Carey… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
G Von Minckwitz, M Untch, JU Blohmer… - Journal of clinical …, 2012 - ascopubs.org
Purpose The exact definition of pathologic complete response (pCR) and its prognostic
impact on survival in intrinsic breast cancer subtypes is uncertain. Methods Tumor response …
impact on survival in intrinsic breast cancer subtypes is uncertain. Methods Tumor response …
[HTML][HTML] Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy
N Houssami, P Macaskill, G von Minckwitz… - European journal of …, 2012 - Elsevier
BACKGROUND: Pathologic complete response (pCR) is a surrogate end-point for prognosis
in neoadjuvant chemotherapy (NAC) for breast cancer. We aimed to report summary …
in neoadjuvant chemotherapy (NAC) for breast cancer. We aimed to report summary …
Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: a meta-analysis
M Huang, J O'Shaughnessy, J Zhao, A Haiderali… - Cancer research, 2020 - AACR
Pathologic complete response (pCR) following neoadjuvant therapy has been associated
with improved event-free survival (EFS) and overall survival (OS) in early-stage breast …
with improved event-free survival (EFS) and overall survival (OS) in early-stage breast …
Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update
J Bohlius, K Bohlke, R Castelli, B Djulbegovic… - Blood …, 2019 - ashpublications.org
Abstract Purpose: To update the American Society of Clinical Oncology (ASCO)/American
Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents …
Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents …
Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 …
A Berruti, V Amoroso, F Gallo, V Bertaglia… - Journal of clinical …, 2014 - ascopubs.org
Purpose To assess the role of pathologic complete response (pCR) after neoadjuvant
therapy as surrogate end point of disease-free survival (DFS) and overall survival (OS) in …
therapy as surrogate end point of disease-free survival (DFS) and overall survival (OS) in …
Alternatives to blood transfusion
DR Spahn, LT Goodnough - The Lancet, 2013 - thelancet.com
The use of alternatives to allogeneic blood continues to rest on the principles that blood
transfusions have inherent risks, associated costs, and affect the blood inventory available …
transfusions have inherent risks, associated costs, and affect the blood inventory available …
Erythropoietin or darbepoetin for patients with cancer
T Tonia, A Mettler, N Robert… - Cochrane database …, 2012 - cochranelibrary.com
Background Anaemia associated with cancer and cancer therapy is an important clinical
factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant …
factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant …